The expanded indication allows esketamine nasal spray to be used as a standalone treatment in adults with MDD who have not ...

Spravato is now the first stand-alone therapy for treatment-resistant depression, for patients who haven't responded to oral ...

The Food and Drug Administration on Tuesday approved Johnson & Johnson's nasal spray to be used alone in adults with a major ...

The announcement was welcome news for those with major depressive disorder, affecting an estimated 8.3% of the adult ...

Johnson & Johnson has announced that the U.S. Food and Drug Administration has approved Spravato (esketamine) CIII nasal ...

"Treatment-resistant depression can be very complicated, especially for patients who do not respond to oral antidepressants ...

J&J on Tuesday said the green light makes Spravato the first and only monotherapy for adults with major depressive disorder who have had an inadequate response to at least two oral antidepressants.

FDA approves Johnson & Johnson's Spravato nasal spray as a monotherapy for major depressive disorder, showing superior ...

People using weed for medical purposes are as likely -- or more -- to become addicted to cannabis as recreational tokers, a ...

Spravato, okayed for stand-alone use among adults, is the first such therapy for major depressive disorder (MDD) that is ...

President Donald Trump and Republicans in Congress should take several steps to further restrict abortion and protect human ...

Amid a deluge of executive actions, the Trump administration has directed federal health agencies to pause external ...